Purpose:We assessed the safety and efficacy of 2 injections of platelet-rich plasma for treating mild to moderate erectile dysfunction by conducting a prospective, randomized, double-blind, placebo-controlled clinical trial.Materials and Methods:Men with mild to moderate erectile dysfunction (International Index of Erectile Function scores 11-25) were randomized to receive either 2 injections of platelet-rich plasma or placebo separated by 1 month. Primary outcome was percentage of men meeting minimum clinically important difference at 1 month after the second injection. Secondary outcomes were change in International Index of Erectile Function at 1, 3, and 6 months, and changes in penile vascular parameters and adverse events at 6 months.Results:We randomized 61 men: 28 into platelet-rich plasma and 33 into placebo. There was no difference between groups in percentage of men meeting minimum clinically important difference at 1 month: 14 (58.3%) in platelet-rich plasma vs 15 (53.6%) in placebo (P = .730). Mean International Index of Erectile Function–Erectile Function domain changed from 17.4 (95% CI 15.8-19.0) to 21 (17.9-24.0) at 1 month in men receiving platelet-rich plasma, vs 18.6 (17.3-19.8) to 21.6 (19.1-24.1) in the placebo group; however, there was no significant difference between groups (P = .756). There were no major adverse events and only 1 minor adverse event in each group. There were no changes in penile Doppler parameters from baseline to 6 months.Conclusions:The results of our prospective, double-blind, randomized, placebo-controlled clinical trial suggest that 2 injections of intracavernosal platelet-rich plasma separated by 1 month in men with mild to moderate erectile dysfunction is safe, but we found no difference in efficacy between platelet-rich plasma and placebo.
Brattleboro rats with a genetic defectin antidiuretic hormone (ADH) synthesis are profoundly polydipsic and have a substantially at-tenuated light-dark distribution of drinking when compared to intact rats maintained on an alter-nating cycle of 12 h of light and 12 h of darkness. Twice daily injections of vasopressin tannate markedly reduced water consumption of Brattle-boro rats and also re-established nearly normal nocturnal drinking patterns. The depressive effects of constant light on water intake of albino rats were abolished by nephrectomy; this response may ordinarily depend on ADH-mediated renal water retention. The light-mediated decrease in fluid intake was attenuated by adrenalectomy although nocturnal drinking patterns and phase-shifting of drinking rhythms were normal in these rats. Intact Long-Evans rats were far less responsive than albino rats in that they did not decrease their daily water intake when placed in constant light; responsiveness to continuous illumination was increased in Long-Evans rats by lesions that bilaterally interrupted the superior accessory and primary optic tracts. These components of the central visual projections may inhibit responsiveness to constant light, possibly by modulating activity of the inferior accessory optic tracts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.